


- 34 -

Claims

1. A compound of formula (I):



(I)

wherein:

Ring A is pyridin-2-yl or thiazol-2-yl; wherein said pyridin-2-yl or thiazol-2-yl may be optionally substituted on carbon by one or more groups selected from R⁴;

One of R¹ and R² is hydrogen and the other is hydrogen or C₁₋₄alkyl; wherein R¹ and R² may be substituted on carbon by one or more groups selected from R⁵;

R³ is selected from C₁₋₄alkyl, C₁₋₄alkoxy, carbocyclyl, heterocyclyl, carbocyclyloxy and heterocyclyloxy; wherein R³ may be independently optionally substituted on carbon by one or more groups selected from R⁶; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by C₁₋₄alkyl;

R⁴ is selected from halo, carboxy and C₁₋₄alkyl;

R⁵ and R⁶ are independently selected from halo, C₁₋₄alkyl, C₁₋₄alkoxy, *N*-(C₁₋₄alkyl)amino, *N,N*-(C₁₋₄alkyl)₂amino, carbocyclyl, heterocyclyl, carbocyclyloxy, heterocyclyloxy and carbocyclylidenyl; wherein R⁵ and R⁶ may be independently optionally substituted on carbon by one or more R⁷; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by C₁₋₄alkyl;

R⁷ is selected from halo, carboxy, methyl, ethyl, methoxy, ethoxy, methylamino, ethylamino, dimethylamino, diethylamino and *N*-methyl-*N*-ethylamino; or a salt, solvate or pro-drug thereof.

2. A compound according to Claim 1 wherein Ring A is unsubstituted or is substituted by carboxy.

3. A compounds according to any one of the preceding claims wherein one of R¹ and R² is hydrogen and the other is hydrogen or C₁₋₄alkyl.

- 35 -

4. A compound according to any one of the preceding claims wherein R^3 is selected from C_{1-4} alkoxy; wherein R^3 may be independently optionally substituted on carbon by one or more groups selected from R^6 .

5

5. A compound according to any one of the preceding claims wherein R^3 is selected from 2-fluorobenzyloxy, 5-methylisoxazol-3-ylmethoxy and 2-thien-3-ylethoxy

6. A compound according to Claim 1 selected from:

10

2-methyl-4-isobutoxy-6-[*N*-(5-carboxypyridin-2-yl)carbamoyl]benzofuran;

2-methyl-4-(2-fluorophenylmethoxy)-6-[*N*-(5-carboxypyridin-2-yl)carbamoyl]benzofuran;

2-methyl-4-isobutoxy-6-[*N*-(5-carboxythiazol-2-yl)carbamoyl]benzofuran;

15

2-methyl-4-(5-methylisoxazol-3-ylmethoxy)-6-[*N*-(5-carboxypyridin-2-yl)carbamoyl]benzofuran;

4-(2-fluorophenylmethoxy)-6-[*N*-(5-carboxypyridin-2-yl)carbamoyl]benzofuran;

4-(5-methylisoxazol-3-ylmethoxy)-6-[*N*-(5-carboxypyridin-2-yl)carbamoyl]benzofuran;

20

2-methyl-4-(thien-2-ylethoxy)-6-[*N*-(5-carboxypyridin-2-yl)carbamoyl]benzofuran;
and

2-methyl-4-isobutoxy-6-[*N*-(thiazol-2-yl)carbamoyl]benzofuran;

or a salt, solvate or pro-drug thereof.

7. A pharmaceutical composition comprising a compound according to any one of Claims 1 to 6, or a salt, pro-drug or solvate thereof, together with a pharmaceutically acceptable diluent or carrier.

25


8. A compound according to any one of Claims 1 to 6 for use in the preparation of a medicament for treatment of a disease mediated through GLK.

30

9. A process for preparing a compound of formula (I), as defined in Claim 1, or a salt, solvate or pro-drug thereof which process (wherein variable groups are, unless otherwise specified, as defined in Claim 1) comprises:


- 36 -

Process 1): reacting an acid of formula (II):




(II)

or an activated derivative thereof; with a compound of formula (III); or



(III)

Process 2) for compounds of formula (I) wherein R⁴ is carboxy; deprotecting a compound of formula (III):



(III)

wherein R^xC(O)O- is an ester group;

and thereafter if necessary or desirable:

- i) converting a compound of the formula (I) into another compound of the formula (I); and/or
- ii) removing any protecting groups; and/or
- iii) forming a salt, solvate or pro-drug thereof.

10. A compound of formula (III) as defined in Claim 9.